European Pharmaceutical Review

NOVEMBER 22, 2023

The small molecule treatment is indicated as a first-line maintenance treatment for individuals with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy. ” The EC based its approval the Phase III ATHENA-MONO study results.

Chemotherapy 98

Chemotherapy Labelling 98

RX Note

JULY 29, 2023

In fact, off-label drug uses can become widely entrenched in clinical practice and become predominant treatments for a given clinical condition. In a study published in JAMA Internal Medicine , off-label use lacking strong scientific evidence had a higher adverse drug event rate compared with on-label use.

Labelling 40

Labelling Dosage Immunization Immunity 40

pharmaphorum

SEPTEMBER 26, 2022

The Ministry of Health, Labour and Welfare (MHLW) in Japan has cleared Ezharmia (valemetostat tosylate) based on the results of an open-label phase 2 trial which revealed a 48% overall response rate with the drug in previously-treated ATL patients.

Chemotherapy 98

Chemotherapy Labelling 98

RX Note

JULY 29, 2023

Nonetheless, there are also circumstances where we have to read up the clinical practice guidelines or clinical journals to justify the dosing of a particular drug, especially those off-label indications. Hence, with a dosing of 1 mg, an ampoule of 3mg granisetron can be used for 3 patients, making it very cost effective.

Chemotherapy 40

Chemotherapy Labelling 40